Ryan Wong is a Director within the Oncology Cell Therapy Safety department at AstraZeneca where he is responsible for overseeing the pre-clinical safety of AstraZeneca’s Cell therapy portfolio in Oncology.
Ryan holds a PhD in Immunology and Clinical Research from Cardiff University and has over 10 years of experience leading immuno-oncology programs in academic settings as well as at several biotech and pharmaceutical companies. He is an established leader having driven the development of multiple cell therapy products in the Oncology space, spanning early discovery through to phase I clinical trials. His breath of experience extends to different therapeutic modalities including bi-specific antibodies, stem cell derived therapies, genome editing as well as both autologous and allogeneic TCR and CAR T cell therapies.
Through-out his career, Ryan has championed collaboration, establishing and leading successful industrial and academic partnerships with the likes of Amgen, Astellas, Celgene, GSK, University of Washington and University of Pennsylvania. He also sits on various leadership teams both in AstraZeneca as well as in his previous roles.